Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$2.59
+4.0%
$3.43
$2.37
$7.63
$328.05M1.42745,849 shs1.04 million shs
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$26.08
$26.08
$14.10
$26.09
$3.24B0.52633,228 shs1,000 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.04
-5.5%
$1.15
$0.85
$2.72
$312.09M2.199.59 million shs10.36 million shs
Quanterix Co. stock logo
QTRX
Quanterix
$5.24
-0.8%
$5.48
$4.05
$19.18
$203.46M1.12575,235 shs397,791 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
+4.02%+5.71%-30.93%-42.32%-55.03%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
0.00%0.00%0.00%0.00%+8.53%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-5.45%+10.46%-6.31%-28.28%-42.86%
Quanterix Co. stock logo
QTRX
Quanterix
-0.76%+8.49%-13.39%-30.96%-67.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.6575 of 5 stars
4.12.00.00.02.11.70.6
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.9639 of 5 stars
3.31.00.00.03.40.01.3
Quanterix Co. stock logo
QTRX
Quanterix
2.1683 of 5 stars
3.32.00.00.02.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.20
Hold$5.60116.22% Upside
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
0.00
N/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.56
Moderate Buy$2.34124.89% Upside
Quanterix Co. stock logo
QTRX
Quanterix
2.50
Moderate Buy$15.60197.71% Upside

Current Analyst Ratings Breakdown

Latest PACB, OLK, QTRX, and CTKB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $7.00
5/15/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.25
5/15/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$1.80 ➝ $1.80
5/13/2025
Quanterix Co. stock logo
QTRX
Quanterix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/12/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$3.50 ➝ $3.00
5/9/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$4.00
4/30/2025
Quanterix Co. stock logo
QTRX
Quanterix
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Quanterix Co. stock logo
QTRX
Quanterix
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$12.00 ➝ $8.00
4/10/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/25/2025
Quanterix Co. stock logo
QTRX
Quanterix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/25/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $2.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$197.05M1.66$0.01 per share206.16$2.90 per share0.89
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$170.89M18.98N/AN/A$4.04 per share6.46
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$152.36M2.05N/AN/A$2.62 per share0.40
Quanterix Co. stock logo
QTRX
Quanterix
$133.92M1.52N/AN/A$9.25 per share0.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/AN/A-5.05%-2.58%-2.05%8/5/2025 (Estimated)
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
-$31.60M-$0.27N/A1,304.00N/A-19.72%-7.07%-6.05%N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$308.65M-$2.79N/AN/AN/A-200.40%-42.89%-14.77%8/6/2025 (Estimated)
Quanterix Co. stock logo
QTRX
Quanterix
-$28.35M-$1.30N/AN/AN/A-30.12%-11.74%-9.66%8/14/2025 (Estimated)

Latest PACB, OLK, QTRX, and CTKB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Quanterix Co. stock logo
QTRX
Quanterix
-$0.69-$0.53+$0.16-$0.53$28.27 million$30.33 million
5/8/2025Q1 2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.04-$0.09-$0.05-$0.09$43.18 million$41.46 million
5/8/2025Q1 2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.19-$0.15+$0.04-$1.44$36.90 million$37.15 million
3/17/2025Q4 2024
Quanterix Co. stock logo
QTRX
Quanterix
-$0.27-$0.30-$0.03-$0.30$34.93 million$35.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Quanterix Co. stock logo
QTRX
Quanterix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.21
5.47
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/A
5.60
3.91
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.97
9.74
8.64
Quanterix Co. stock logo
QTRX
Quanterix
N/A
10.07
9.16

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
30.19%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
Quanterix Co. stock logo
QTRX
Quanterix
86.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500126.66 million116.45 millionOptionable
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
420124.34 million117.88 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730300.09 million267.29 millionOptionable
Quanterix Co. stock logo
QTRX
Quanterix
46038.83 million35.87 millionOptionable

Recent News About These Companies

Brokerages Set Quanterix Co. (NASDAQ:QTRX) PT at $15.60
Quanterix: Hard To Make A Good Diagnosis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$2.59 +0.10 (+4.02%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$2.64 +0.05 (+1.93%)
As of 05/29/2025 07:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Olink Holding AB (publ) stock logo

Olink Holding AB (publ) NASDAQ:OLK

Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services. In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.04 -0.06 (-5.45%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.04 +0.00 (+0.48%)
As of 05/29/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Quanterix stock logo

Quanterix NASDAQ:QTRX

$5.24 -0.04 (-0.76%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$5.24 0.00 (0.00%)
As of 05/29/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.